Weil has been recognized with two awards at the 2022 International Financial Law Review Asia-Pacific Awards, highlighting the market-leading dealmaking expertise of Weil Asia’s Private Equity practice and its attorneys.

Weil received honors for its work as international counsel on the landmark US$4.76 billion take-private of leading plasma producer China Biologic Products Holdings, which has been named “Deal of the Year – Private Equity.” The Weil team members involved in this transaction include Chris Welty and Jie Yuan.

In addition, Banking & Finance counsel Kevin Yao has been named “Rising Star,” an honor given only to the top three attorneys across all the leading international law firms who are recognized as the next generation of leading lawyers.

The IFLR Asia-Pacific Awards recognize the year’s most innovative and accomplished deals, legal teams and attorneys in the Asia-Pacific region.